MBIO: the cash flow

MyFinsight

MUSTANG BIO, INC. (MBIO)

Cash Flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Net loss	-955	-538	-468	-915
Issuance of common shares - equity fee on equity offerings to fortress biotech	0	0	179	216
Common shares issuable - annual stock dividend to fortress biotech	NaN	273	NaN	NaN
Research and development - licenses acquired	NaN	0	NaN	NaN
Loss on disposal of property and equipment	NaN	0	0	0
Stock-based compensation expenses	22	23	23	83
Depreciation expense	0	0	0	34
Asset impairment	NaN	0	0	0
Amortization of operating lease right-of-use assets	0	0	0	7
Settlement of payables	76	731	577	796
Gain on lease termination	0	0	0	394
Prepaid expenses and other assets	-3	-50	-12	-28
Other receivables	0	0	0	-435
Accounts payable and accrued expenses	-20	-769	-12	-1,190
Payable and accrued expenses - related party	18	-26	25	-163
Deferred income	NaN	0	NaN	NaN
Lease liabilities	0	0	0	73
Net cash used in operating activities	-1,008	-1,718	-818	-2,728
Proceeds from the sale of property and equipment	0	0	0	1,165
Net cash from investing activities	0	0	0	1,165
Proceeds from warrant exercises	NaN	0	7,145	0
Proceeds from issuance of common shares under espp	NaN	0	0	0
Proceeds from issuance of common shares, net of offering costs - equity offering	0	0	0	6,782
Proceeds from issuance of common shares, net of offering costs - at-the-market offering	0	0	0	599
Net cash provided by financing activities	0	0	7,145	7,381
Net change in cash and cash equivalents	-1,008	-1,718	6,327	5,818
Cash and cash equivalents, beginning of the period	17,266	18,984	6,839	NaN
Cash and cash equivalents, end of the period	16,258	17,266	18,984	NaN

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.